Role of Bone Marrow Transplant in the Treatment of Myeloma
Dr. Edward A. Stadtmauer
Washington, DC 2009 Patient & Family Seminar
August 7-8, 2009
|
|
|
10.15.09 |
|
"The Role of Bone Marrow Transplant in the Treatment of Myeloma"
Dr. Edward A. Stadtmauer
Washington 2009 Patient & Family Seminar
To view the video full screen, click on the small  button next to the volume control in the lower right hand corner.
|
 related videos  related articles |
ASH 2009: Andrzej J Jakubowiak
Phase 1/2 Study of Elotuzumab in Combination with Bortezomib in Patients with Multiple Myeloma with One to Three Prior Therapies: Interim Results
ASH 2009: Andrzej J. Jakubowiak
Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial
ASh 2009: Andrzej Jakubowiak
Influence of Cytogenetics in Patients with Relapsed and Refractory Multiple Myeloma (MM) Treated with Carfilzomib (CFZ)
ASH 2009: Asher Chanan-Khan
Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
ASH 2009: Asher Chanan-Khan
Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis
ASH 2009: Attaya Suvannasankha
Phase 2 Clinical Trial of Oral Lenalidomide, Cyclophosphamide, and Prednisone (RCP) for Newly Diagnosed Multiple Myeloma Patients
ASH 2009: Craig Reeder
A Phase II Trial Comparison of Once Versus Twice Weekly Bortezomib in CYBORD Chemotherapy for Newly Diagnosed Myeloma: Identical High Response Rates and Less Toxicity
ASH 2009: Don Benson
Novel Monoclonal Antibody Enhances Natural Killer (NK) Cell Cytotoxicity against Multiple Myeloma (MM): Interim Phase 1 Trial Results
ASH 2009: Elena Zamagni
Incorporation of Thalidomide-Dexamethasone (Thal-Dex) into up-Front Double Autologous Stem-Cell Transplantation (ASCT) for multiple Myeloma: Final analysis of phase II “Bologna 2002” Study
ASH 2009: Evangelos Terpos
Consolidation Therapy with Bortezomib, Thalidomide and Dexamethasone (VTD) Regimen After ASCT in Myeloma Patients Who Do Not Receive Bisphosphonates Reduces Bone Resorption and RANKL/OPG Ratio but Seems to Have No Effect On Bone Formation and Angiogenesis
ASH 2009: Evangelos Terpos
High Serum Lactate Dehydrogenase (LDH) Is An Important Prognostic Factor in the Era of Novel Agents and Adds to the Prognostic Value of the International Staging System (ISS) in Patients with Multiple Myeloma
ASH 2009: Evangelos Terpos
Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or without Bortezomib: Prospective Evaluation of the Impact of Cytogenetic Abnormalities
ASH 2009: Evangelos Terpos
The Addition of Bortezomib to the Combination of Lenalidomide and Dexamethasone Increases Bone Formation in Relapsed/Refractory Myeloma: a Prospective Study in 91 Patients
ASH 2009: Federica Cavallo
A Prospective Randomized Phase I/II Study of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) for Relapsed/Refractory Multiple Myeloma Patients
ASH 2009: Francesca Gay
Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma
ASH 2009: Francesca Gay
Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients
ASH 2009: Francesca Gay
Sequential Approach with Bortezomib as Induction Before Autologous Transplantation, Followed by Lenalidomide as Consolidation-Maintenance in Untreated Multiple Myeloma Patients
ASH 2009: Francesca Gay
The Weekly Infusion of Bortezomib Reduces Peripheral Neuropathy
ASH 2009: Irene Ghobrial
Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma
ASH 2009: Joseph R. Mikhael
Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy in Patients with Relapsed Multiple Myeloma
ASH 2009: Kai Neben
Achievement of CR and nCR Before and After First High-Dose Therapy Followed by Autologous Stem Cell Transplantation Is a Major Marker for Long-Term Survival in Multiple Myeloma Patients
Our apologies, this video is in process and will be posted in the near future.
ASH 2009: Michele Cavo
A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD
ASH 2009: Philip McCarthy
Phase III Intergroup Study of Lenalidomide (CC-5013) Versus Placebo Maintenance Therapy Following Single Autologous Stem Cell Transplant for Multiple Myeloma (CALGB 100104): Initial Report of Patient Accrual and Adverse Events
ASH 2009: Prashant Kapoor
Evidence for Cytogenetic and Fluorescence in Situ Hybridization (FISH) Risk Stratification of Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies
ASH 2009: Prashant Kapoor
Melphalan and Prednisone (MP) Versus Melphalan, Prednisone and Thalidomide (MPT) as Initial Therapy for Previously Untreated Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials
ASH 2009: Preeti Khetarpal
The Impact of Withholding Immunomodulatory Drugs for Stem Cell Mobilization On Disease Activity in Multiple Myeloma
ASH 2009: Rachid Baz
Evaluation of Single Agent Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
ASH 2009: Ravi Vij
Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects
ASH 2009: Swaminathan Padmanabhan
A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx)
ASH 2009: Taimur Sher
Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT), An Effective Steroid Independent Regimen for Previously Untreated Multiple Myeloma Patients: Final Result of a Phase II Study
ASH 2009: Tomer Mark
T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid®], Dexamethasone) Therapy for Upfront Use in Symptomatic Multiple Myeloma
ASH 2009: Tommasina Guglielmelli
Sequential Therapy with IMID’s in Relapsed-Refractory Multiple Myeloma Patients
ASH 2009: Ulf-Henrik Mellqvist
Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial
ASH 2010 Overview from Dr. Kenneth Anderson
Bildgebung beim Multiplen Myelom
"MRT/CT/Röntgen - wann indiziert?"
Bisphophonate -
Ballon Kyphoplastie
Cos'è un protocollo clinico - rispondono data managers and research nurses
Dr. Bladé - A Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma: Superiority of VTD (Bortezomib/Thalidomide/Dexamethasone) Over TD and VBMCP/VBAD Plus Bortezomib
Dr. Bladé - Un resumen de las presentaciones de ASH 2010
Dr. Cavo - Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Induction and Consolidation Therapy Before and After Double Autologous Transplantation In Newly Diagnosed Multiple Myeloma: Results From a Randomized Phase 3 Study
Dr. Dispenzieri - A Phase-2 Study of Pomalidomide and Dexamethasone In Previously-Treated Light-Chain (AL) Amyloidosis
Dr. Jagannath - Long-Term Treatment and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)
Dr. Krishnan - Tandem Autologous Hematopoietic Stem Cell Transplants (AuHCT) with or without Maintenance Therapy (auto-auto) Versus Single AuHCT Followed by HLA Matched Sibling Non- Myeloablative Allogeneic HCT (auto-allo) for Patients with Standard Risk (SR) Multiple Myeloma (MM): Results From the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial
Dr. Kumar - Efficacy of Retreatment with Immunomodulatory Compounds In Patients Receiving Initial Therapy for Newly Diagnosed Multiple Myeloma
Dr. Kumar - Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study
Dr. Kumar - Phase 1 Trial of Sorafenib and Everolimus In Patients with Lymphoma or Multiple Myeloma
Dr. Lacy - Pomalidomide Plus Low-Dose Dexamethasone In Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies In Dual-Refractory Disease
Dr. Leleu - MELISSE, a Large Multicentric Observational Study to Determine Criteria and Risk Factors of Thromboembolism for Patients with Multiple Myeloma Treated with Immunomodulator Drugs
Dr. Lonial - Elotuzumab In Combination with Lenalidomide and Low-Dose Dexamethasone In Patients with Relapsed/Refractory Multiple Myeloma: Interim Results of a Phase 1 Study
Dr. Ludwig - Ein Überblick über den ASH-Kongress 2010
Dr. Ludwig - The Ratio of Monoclonal to Polyclonal Immunoglobulins Assessed with the Hevylite Test Predicts Prognosis, Is Superior for Monitoring the Course of the Disease and Allows Detection of Monoclonal Immunoglobulin In Patients with Normal or Subnormal Involved Immunoglobulin Isotype
Dr. Martin - Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM)
Dr. San Miguel- Un resumen de las presentaciones de ASH 2010
Dr. Sher - Efficacy Analysis From Phase I Study of Lorvotuzumab Mertansine (IMGN901), Used as Monotherapy, In Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Efficacy Analysis
Dr. Sher - Phase I Study of Lorvotuzumab Mertansine (IMGN901) In Combination with Lenalidomide and Dexamethasone In Patients with CD56-Positive Relapsed or Relapsed/Refractory Mulitple Myeloma - A Preliminary Safety and Efficacy Analysis of the Combination
Dr. Siegel - Outcome with Lenalidomide Plus Dexamethasone Followed by Early Autologous Stem Cell Transplantation In the ECOG E4A03 Randomized Clinical Trial
Dr. Siegel - Vorinostat Overcomes Lenalidomide-Dexamethasone and Lenalidomide-Bortezomib-Dexamethasone Resistance In Relapsed/Refractory Multiple Myeloma
Dr. Stewart - A Randomized Phase III Trial of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT) In Patients with Multiple Myeloma (MM): The NCIC CTG MY.10 Trial
Dr. Suvannasankha - Assessment of the Performance of Serum Heavy Chains Immunoassay to Monitor Response to Treatment and Its Correlation with Other Tumor Measurements In Serial Samples From Patients with Newly Diagnosed MM
Dr. Suvannasankha - Phase 2 Clinical Trial of Oral Lenalidomide, Cyclophosphamide, and Prednisone (RCP) for Newly Diagnosed Multiple Myeloma Patients
Dr. Van Ness - Identification of Single Nucleotide Polymorphism Interactions Associated with Survival and Risk In Multiple Myeloma Using Novel Data Mining Methods
Dr. Waage - En oversikt over ASH 2010
Il Ruolo dell'Infermiere in un D.H. di Ematologia: Procedura per Infusione Bortezomib
Knochenmarkdiagnostik
muß dies sein
La terapia del paziente giovane
La terapia del paziente giovane
Los Angeles Patient & Family Seminar
August 28, 2010
Los Angeles Patient & Family Seminar
August 28, 2010
Multiples Myelom - Grundbegriffe
Multiples Myelom: Wann behandeln? Wie kontrollieren?
Neue Klassifikationen des Multiplen Myeloms - Welche Relevanz haben sie für den Patienten?
Neue Substanzen in der Therapie des Multiplen Myeloms
Neue Substanzen: Zukunftsperspektiven in der Therapie des Multiplen Myeloms
Neues vom ASH Kongress 2009
Onkologische Nachsorge
Psychologische Betreuung für Patienten & Angehörige
Allogreff de cellules souches hématopoïétiques
Prof. Jean-Luc Harousseau
Paris 2009 Séminaire - Evolution de la prise en charge du sujet jeune
Traitement de première ligne du myélome multiple chez les patients non éligibles au traitement intensif avec autogreff de CSH
Problemi legati alla terapia
Problemi legati alla terapia
Selbsthilfe und ihre Bedeutung
Un resumen de las presentaciones de ASH 2009
Una visione d’insieme dell’ASH 2009: Antonio Palumbo
Update from ASH 2009:
Sequential Use of Treatments vs. Combinations
Welcome and Introductions
The Small Print
Dr. Brian Durie
Ask-the-Experts
Open Forum Discussion with Dr. Brian G.M. Durie, Dr. Frederick Smith and Dr. Robert Kyle
Managing the Side effects of Novel Agents
Kena Miller,RN, MSN, FNP
How to Be a Good Patient
Michael Katz
Understanding Scientific Literature
Allan Weinstein, PhD
Myeloma 101/Overview
Dr. Robert Kyle
Options for Frontline Therapy
Dr. Brian Durie
Understanding Serum Free Light Chain Assays
Dr. Karen Van Hoeven
Role of Bone Marrow Transplant in the Treatment of Myeloma
Dr. Edward A. Stadtmauer
Bone Disease in Multiple Myeloma
Dr. Brian Durie
IMF Advocacy
Greg Brozeit with Christine Murphy and Arin Assero
Multiple Myeloma: Relapsed Disease
Dr. Sagar Lonial
Ask-the-Experts
Open Forum Discussion with Dr. Brian G.M. Durie, Dr. Frederick Smith and Dr. Robert Kyle
Bone Disease in Multiple Myeloma
Dr. Brian Durie
How to Be a Good Patient
Michael Katz
IMF Advocacy
Greg Brozeit with Christine Murphy and Arin Assero
Managing the Side effects of Novel Agents
Kena Miller,RN, MSN, FNP
Multiple Myeloma: Relapsed Disease
Dr. Sagar Lonial
Myeloma 101/Overview
Dr. Robert Kyle
Options for Frontline Therapy
Dr. Brian Durie
The Small Print
Dr. Brian Durie
Understanding Scientific Literature
Allan Weinstein, PhD
Understanding Serum Free Light Chain Assays
Dr. Karen Van Hoeven
ASH 2009: Andrzej J Jakubowiak
Phase 1/2 Study of Elotuzumab in Combination with Bortezomib in Patients with Multiple Myeloma with One to Three Prior Therapies: Interim Results
ASH 2009: Andrzej J. Jakubowiak
Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial
ASh 2009: Andrzej Jakubowiak
Influence of Cytogenetics in Patients with Relapsed and Refractory Multiple Myeloma (MM) Treated with Carfilzomib (CFZ)
ASH 2009: Asher Chanan-Khan
Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
ASH 2009: Asher Chanan-Khan
Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis
ASH 2009: Attaya Suvannasankha
Phase 2 Clinical Trial of Oral Lenalidomide, Cyclophosphamide, and Prednisone (RCP) for Newly Diagnosed Multiple Myeloma Patients
ASH 2009: Brian Durie
Bank On A Cure®
ASH 2009: Craig Reeder
A Phase II Trial Comparison of Once Versus Twice Weekly Bortezomib in CYBORD Chemotherapy for Newly Diagnosed Myeloma: Identical High Response Rates and Less Toxicity
ASH 2009: Don Benson
Novel Monoclonal Antibody Enhances Natural Killer (NK) Cell Cytotoxicity against Multiple Myeloma (MM): Interim Phase 1 Trial Results
ASH 2009: Elena Zamagni
Incorporation of Thalidomide-Dexamethasone (Thal-Dex) into up-Front Double Autologous Stem-Cell Transplantation (ASCT) for multiple Myeloma: Final analysis of phase II “Bologna 2002” Study
ASH 2009: Evangelos Terpos
Consolidation Therapy with Bortezomib, Thalidomide and Dexamethasone (VTD) Regimen After ASCT in Myeloma Patients Who Do Not Receive Bisphosphonates Reduces Bone Resorption and RANKL/OPG Ratio but Seems to Have No Effect On Bone Formation and Angiogenesis
ASH 2009: Evangelos Terpos
High Serum Lactate Dehydrogenase (LDH) Is An Important Prognostic Factor in the Era of Novel Agents and Adds to the Prognostic Value of the International Staging System (ISS) in Patients with Multiple Myeloma
ASH 2009: Evangelos Terpos
Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or without Bortezomib: Prospective Evaluation of the Impact of Cytogenetic Abnormalities
ASH 2009: Evangelos Terpos
The Addition of Bortezomib to the Combination of Lenalidomide and Dexamethasone Increases Bone Formation in Relapsed/Refractory Myeloma: a Prospective Study in 91 Patients
ASH 2009: Federica Cavallo
A Prospective Randomized Phase I/II Study of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) for Relapsed/Refractory Multiple Myeloma Patients
ASH 2009: Francesca Gay
Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma
ASH 2009: Francesca Gay
Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients
ASH 2009: Francesca Gay
Sequential Approach with Bortezomib as Induction Before Autologous Transplantation, Followed by Lenalidomide as Consolidation-Maintenance in Untreated Multiple Myeloma Patients
ASH 2009: Francesca Gay
The Weekly Infusion of Bortezomib Reduces Peripheral Neuropathy
ASH 2009: Hervé Avet Loiseau
Induction with Velcade®/Dexamethasone Partially Overcomes the Poor Prognosis of t(4;14), but Not That of Del(17p), in Young Patients with Multiple Myeloma
ASH 2009: Irene Ghobrial
Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma
ASH 2009: Joseph R. Mikhael
Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy in Patients with Relapsed Multiple Myeloma
ASH 2009: Kai Neben
Achievement of CR and nCR Before and After First High-Dose Therapy Followed by Autologous Stem Cell Transplantation Is a Major Marker for Long-Term Survival in Multiple Myeloma Patients
ASH 2009: Maria-Victoria Mateos
A Prospective, Multicenter, Randomized, Trial of Bortezomib/Melphalan/Prednisone (VMP) Versus Bortezomib/Thalidomide/Prednisone (VTP) as Induction Therapy Followed by Maintenance Treatment with Bortezomib/Thalidomide (VT) Versus Bortezomib/Prednisone (VP) in Elderly Untreated Patients with Multiple Myeloma Older Than 65 Years
ASH 2009: Michele Cavo
A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD
ASH 2009: Philip McCarthy
Phase III Intergroup Study of Lenalidomide (CC-5013) Versus Placebo Maintenance Therapy Following Single Autologous Stem Cell Transplant for Multiple Myeloma (CALGB 100104): Initial Report of Patient Accrual and Adverse Events
ASH 2009: Prashant Kapoor
Evidence for Cytogenetic and Fluorescence in Situ Hybridization (FISH) Risk Stratification of Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies
ASH 2009: Prashant Kapoor
Melphalan and Prednisone (MP) Versus Melphalan, Prednisone and Thalidomide (MPT) as Initial Therapy for Previously Untreated Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials
ASH 2009: Preeti Khetarpal
The Impact of Withholding Immunomodulatory Drugs for Stem Cell Mobilization On Disease Activity in Multiple Myeloma
ASH 2009: Rachid Baz
Evaluation of Single Agent Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
ASH 2009: Ravi Vij
Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects
ASH 2009: Swaminathan Padmanabhan
A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx)
ASH 2009: Taimur Sher
Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT), An Effective Steroid Independent Regimen for Previously Untreated Multiple Myeloma Patients: Final Result of a Phase II Study
ASH 2009: Tomer Mark
T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid®], Dexamethasone) Therapy for Upfront Use in Symptomatic Multiple Myeloma
ASH 2009: Tommasina Guglielmelli
Sequential Therapy with IMID’s in Relapsed-Refractory Multiple Myeloma Patients
ASH 2009: Ulf-Henrik Mellqvist
Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial
ASH 2009
Hervé Avet Loiseau
Deletion of the 17p Chromosomal Region Is Associated with a Very Poor Outcome in Multiple Myeloma Independently of the Type of Treatment
ASH 2010 Overview from Dr. Kenneth Anderson
Bildgebung beim Multiplen Myelom
"MRT/CT/Röntgen - wann indiziert?"
Bisphophonate
Ballon Kyphoplastie
Cos'è un protocollo clinico - rispondono data managers and research nurses
Dr. Bladé - A Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma: Superiority of VTD (Bortezomib/Thalidomide/Dexamethasone) Over TD and VBMCP/VBAD Plus Bortezomib
Dr. Bladé - Un resumen de las presentaciones de ASH 2010
Dr. Cavo - Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Induction and Consolidation Therapy Before and After Double Autologous Transplantation In Newly Diagnosed Multiple Myeloma: Results From a Randomized Phase 3 Study
Dr. Dispenzieri - A Phase-2 Study of Pomalidomide and Dexamethasone In Previously-Treated Light-Chain (AL) Amyloidosis
Dr. Jagannath - Long-Term Treatment and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)
Dr. Krishnan - Tandem Autologous Hematopoietic Stem Cell Transplants (AuHCT) with or without Maintenance Therapy (auto-auto) Versus Single AuHCT Followed by HLA Matched Sibling Non- Myeloablative Allogeneic HCT (auto-allo) for Patients with Standard Risk (SR) Multiple Myeloma (MM): Results From the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial
Dr. Kumar - Efficacy of Retreatment with Immunomodulatory Compounds In Patients Receiving Initial Therapy for Newly Diagnosed Multiple Myeloma
Dr. Kumar - Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study
Dr. Kumar - Phase 1 Trial of Sorafenib and Everolimus In Patients with Lymphoma or Multiple Myeloma
Dr. Lacy - Pomalidomide Plus Low-Dose Dexamethasone In Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies In Dual-Refractory Disease
Dr. Leleu - MELISSE, a Large Multicentric Observational Study to Determine Criteria and Risk Factors of Thromboembolism for Patients with Multiple Myeloma Treated with Immunomodulator Drugs
Dr. Lonial - Elotuzumab In Combination with Lenalidomide and Low-Dose Dexamethasone In Patients with Relapsed/Refractory Multiple Myeloma: Interim Results of a Phase 1 Study
Dr. Ludwig - Ein Überblick über den ASH-Kongress 2010
Dr. Ludwig - The Ratio of Monoclonal to Polyclonal Immunoglobulins Assessed with the Hevylite Test Predicts Prognosis, Is Superior for Monitoring the Course of the Disease and Allows Detection of Monoclonal Immunoglobulin In Patients with Normal or Subnormal Involved Immunoglobulin Isotype
Dr. Martin - Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM)
Dr. San Miguel- Un resumen de las presentaciones de ASH 2010
Dr. Sher - Efficacy Analysis From Phase I Study of Lorvotuzumab Mertansine (IMGN901), Used as Monotherapy, In Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Efficacy Analysis
Dr. Sher - Phase I Study of Lorvotuzumab Mertansine (IMGN901) In Combination with Lenalidomide and Dexamethasone In Patients with CD56-Positive Relapsed or Relapsed/Refractory Mulitple Myeloma - A Preliminary Safety and Efficacy Analysis of the Combination
Dr. Siegel - Outcome with Lenalidomide Plus Dexamethasone Followed by Early Autologous Stem Cell Transplantation In the ECOG E4A03 Randomized Clinical Trial
Dr. Siegel - Vorinostat Overcomes Lenalidomide-Dexamethasone and Lenalidomide-Bortezomib-Dexamethasone Resistance In Relapsed/Refractory Multiple Myeloma
Dr. Stewart - A Randomized Phase III Trial of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT) In Patients with Multiple Myeloma (MM): The NCIC CTG MY.10 Trial
Dr. Suvannasankha - Assessment of the Performance of Serum Heavy Chains Immunoassay to Monitor Response to Treatment and Its Correlation with Other Tumor Measurements In Serial Samples From Patients with Newly Diagnosed MM
Dr. Suvannasankha - Phase 2 Clinical Trial of Oral Lenalidomide, Cyclophosphamide, and Prednisone (RCP) for Newly Diagnosed Multiple Myeloma Patients
Dr. Van Ness - Identification of Single Nucleotide Polymorphism Interactions Associated with Survival and Risk In Multiple Myeloma Using Novel Data Mining Methods
Dr. Waage - En oversikt over ASH 2010
Il Ruolo dell'Infermiere in un D.H. di Ematologia: Procedura per Infusione Bortezomib
Introduction and Bone Disease in Myeloma
Knochenmarkdiagnostik
muß dies sein
La terapia del paziente giovane
La terapia del paziente giovane
Los Angeles Patient & Family Seminar
August 28, 2010
Los Angeles Patient & Family Seminar
August 28, 2010
Multiples Myelom - Grundbegriffe
Multiples Myelom: Wann behandeln? Wie kontrollieren?
Neue Klassifikationen des Multiplen Myeloms - Welche Relevanz haben sie für den Patienten?
Neue Substanzen in der Therapie des Multiplen Myeloms
Neue Substanzen: Zukunftsperspektiven in der Therapie des Multiplen Myeloms
Neues vom ASH Kongress 2009
Onkologische Nachsorge
Psychologische Betreuung für Patienten & Angehörige
Paris 2009 Séminaire - Allogreff de cellules souches hématopoïétiques
Paris 2009 Séminaire - Evolution de la prise en charge du sujet jeune
Paris 2009 Séminaire - Questions et Réponses
Paris 2009 Séminaire - Traitement de première ligne du myélome multiple chez les patients non éligibles au traitement intensif avec autogreff de CSH
Problemi legati alla terapia
Problemi legati alla terapia
Selbsthilfe und ihre Bedeutung
Un resumen de las presentaciones de ASH 2009
Una visione d’insieme dell’ASH 2009: Antonio Palumbo
Update from ASH 2009:
Novel Agents
Update from ASH 2009:
Sequential Use of Treatments vs. Combinations
Welcome and Introductions
|
|
|
You are going to be hearing presentations from doctors, but they are not your doctor. So take this information to your doctor to help shape a plan for moving forward. |
|
|
|
|
Washington, DC 2009 Patient & Family Seminar
August 7-8, 2009
|
|
|
|
|
Washington, DC 2009 Patient & Family Seminar
August 7-8, 2009
|
|
|
|
|
Washington, DC 2009 Patient & Family Seminar
August 7-8, 2009
|
|
|
|
|
Washington, DC 2009 Patient & Family Seminar
August 7-8, 2009
|
|
|
|
|
Washington, DC 2009 Patient & Family Seminar
August 7-8, 2009 |
|
|
|
|
Washington, DC 2009 Patient & Family Seminar
August 7-8, 2009
|
|
|
|
|
|
Washington, DC 2009 Patient & Family Seminar
August 7-8, 2009
|
|
|
|
|
Washington, DC 2009 Patient & Family Seminar
August 7-8, 2009 |
|
|
|
|
Washington, DC 2009 Patient & Family Seminar
August 7-8, 2009 |
|
|
|
|
Washington, DC 2009 Patient & Family Seminar
August 7-8, 2009
|
|
back
print
